Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event (Details)

v3.20.2
Subsequent Event (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 21, 2020
Oct. 09, 2020
Oct. 31, 2020
Dec. 31, 2020
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2017
Dec. 31, 2015
Subsequent Event                      
Payments to acquire milestones and royalties                 $ 19,300    
Bad debt allowance         $ 1,409     $ 1,409      
Provision for bad debt               1,409      
Accounts Receivable, Allowance for Credit Loss         1,409     1,409      
Revenue from contracts with customers         200   $ 8,525 753 17,176    
License Agreement | Novartis International                      
Subsequent Event                      
Revenue from contracts with customers         0   $ 0 0 $ 0 $ 10,000 $ 37,000
License Agreement | Rezolute                      
Subsequent Event                      
Bad debt allowance         1,400     1,400      
Provision for bad debt           $ 1,400          
Accounts Receivable, Allowance for Credit Loss         1,400     1,400      
Revenue from contracts with customers         $ 0     $ 0      
Subsequent Event | Forecast                      
Subsequent Event                      
Provision for bad debt       $ (1,400)              
Subsequent Event | License Agreement | Novartis International                      
Subsequent Event                      
Revenue from contracts with customers $ 25,000                    
Cash receivable 17,700                    
Subsequent Event | License Agreement | Novartis International | Forecast                      
Subsequent Event                      
Revenue from contracts with customers       $ 25,000              
Subsequent Event | License Agreement | Rezolute                      
Subsequent Event                      
Future cash payments received     $ 1,400                
Subsequent Event | Second Royalty Purchase Agreement | Bioasis Technologies Inc                      
Subsequent Event                      
Payments to acquire milestones and royalties     $ 1,200                
Subsequent Event | Rezolute | Private Placement                      
Subsequent Event                      
Aggregate gross proceeds from issuance of common stock   $ 41,000                  
Novartis Note | Subsequent Event                      
Subsequent Event                      
Reduction in debt obligation $ 7,300